Proton pump inhibitors (PPIs) are widely prescribed to mechanically ventilated patients to prevent gastrointestinal (GI) bleeding. The evidence for their use is not strong; individual randomized trials have not shown a clear benefit over histamine blockers, but when many trials were pooled into meta-analyses, PPIs do appear to be superior. The Surviving Sepsis Guidelines have [… read more]
About one in five patients with cancer will develop pulmonary embolism (PE) or deep venous thrombosis (DVT), together called venous thromboembolism (VTE). Cancer patients who develop VTE are four times more likely to have experience another (recurrent) DVT or PE. Twice-daily injections of enoxaparin are advised for patients with cancer-related DVT/PE, or who are at [… read more]
by Molly Walker, Staff Writer, MedPage Today Omadacycline, a novel antibiotic in the tetracycline class, was non-inferior to standard of care for both community-acquired bacterial pneumonia and acute bacterial skin and skin-structure infections, two randomized trials found. There was no significant difference in early clinical response among patients with community-acquired bacterial pneumonia randomized to omadacycline and those [… read more]
(From Dr. Philippe Rola) Join us for a couple of days of awesome learning in an awesome city! Back, bigger and better for its second iteration, this multispecialty cross-training exercise brings you the cutting and bleeding edge of acute care management of the sick patient, from the ED to the wards or the ICU. Combining [… read more]
Stethoscopes have always been an obvious suspect in the transmission of infections to patients by health care professionals. They’re carried room to room, come in contact with each patient, and are almost never disinfected between patient contacts. Testing has shown just what one would expect: stethoscopes are often contaminated with bacteria. One of the latest [… read more]
Most families have never suffered through a loved one experiencing prolonged critical illness and respiratory failure (defined as ventilator dependence for weeks, usually with a tracheostomy). But each year, more do. An estimated 400,000 people currently live with chronic critical illness in long-term acute care hospitals (LTACHs) and other facilities — a population that has [… read more]
by Salynn Boyles, Contributing Writer, MedPage Today Treatment with antibiotics during hospitalization for asthma exacerbation was associated with longer hospital stays and higher hospital costs in a retrospective cohort study of nearly 20,000 adult patients. Mihaela Stefan, MD, PhD, of the University of Massachusetts Medical School in Springfield, and colleagues, found that despite guidelines recommending against routine [… read more]
The U.S. FDA approved the first generic version of blockbuster drug Advair (fluticasone/salmeterol) for asthma maintenance treatment in patients aged 4 and up, and also for maintenance treatment and prevention of exacerbations in chronic obstructive pulmonary disease (COPD). Mylan will make the generic alternative to fluticasone/salmeterol, which will be called Wixela Inhub and come in [… read more]
Theophylline is derived from methylxanthine, naturally present in tea and cocoa beans. Initially used medically in 1895 as a diuretic, theophylline was one of the first drugs for asthma and COPD/emphysema (beginning in 1922), after its bronchodilation effects were discovered. Theophylline also has cardiac and central nervous system stimulant side effects and can produce tachyarrhythmias [… read more]
The U.S. Food and Drug Administration (FDA) approved baloxavir marboxil, an oral tablet to be marketed as Xofluza, for treatment of early acute uncomplicated influenza in adolescents and adults. FDA Commissioner Scott Gottlieb said in a news release, This is the first new antiviral flu treatment with a novel mechanism of action approved by the FDA [… read more]
After a review of reported adverse events, the U.S. FDA is warning physicians that fluoroquinolone antibiotics may increase the occurrence of aortic dissections, resulting in aortic rupture and death. FDA used unusually direct language in advising, “Fluoroquinolones should not be used in patients at increased risk unless there are no other treatment options available.” Patients [… read more]
Pressing fingers against the cricoid cartilage (the Sellick maneuver) during rapid sequence intubation compresses the esophagus beneath the firmer trachea. It has long been espoused that this prevents aspiration (emesis or reflux of gastric contents into the supraglottic space and airway, obscuring the operator’s view and harming the patient). The Sellick maneuver is believed to [… read more]
Tennessee law enforcement agents announced they had arrested and charged a nurse with reckless homicide and patient abuse for a fatal medication error she allegedly committed while working at Vanderbilt University Medical Center in December 2017. The charges allege that the nurse intended to provide an ordered dose of midazolam (Versed) to an anxious patient [… read more]
A large proportion of patients who remain in ICUs for more than a few days develop hospital-acquired infections, including bloodstream infections. Indwelling urinary or venous catheters, gut translocation, aspiration and impaired host defenses can all be causative. Bloodstream infection incidence has been reduced over time, but remains persistently ineradicable. One enticing method of prevention has been [… read more]
by John Gever, Managing Editor, MedPage Today WASHINGTON — Primatene Mist, the over-the-counter epinephrine inhaler for quick asthma relief, can go back on the market in a reformulated version, the FDA said. Now using a hydrofluoroalkane (HFA) propellant in place of the banned chlorofluorocarbon (CFC) used in the original Primatene product (and most other asthma inhalers), the new [… read more]
The U.S. Food and Drug Administration (FDA) approved revefenacin inhalation solution to be marketed as Yupelri for ongoing treatment of patients with chronic obstructive pulmonary disease (COPD). Yupelri will be marketed by Theravance Biopharma. Revefenacin is the first once-daily nebulized bronchodilator approved for COPD in the U.S., according to its manufacturer. Revefenacin is a long-acting muscarinic antagonist. In randomized trials, 3 [… read more]
Very little evidence guides nutrition in critical illness. Because of critically ill patients’ catabolic state, and probably influenced by the normalization fallacy, nutrition practices often include efforts to provide daily calories in the 1,800 – 2,000 range. However, anorexia may be adaptive during illness (since it is common to multiple disease states); greater enterally infused [… read more]
By Nicholas Mark, MD During the 1940s, many Melanesian cultures were profoundly altered as the Second World War was waged in the Pacific around them. Western soldiers constructed airstrips out of the jungles and the natives witnessed vast wealth in the form of manufactured goods literally rain down from the skies on parachutes or carried [… read more]
by Salynn Boyles, Contributing Writer, MedPage Today Vitamin D supplements reduced moderate to severe COPD exacerbations in patients with low circulating levels of its 25-hydroxyvitamin D (25-OH-D) metabolite at baseline, a meta-analysis indicated. But no such effect was seen for patients with at least normal 25-OH-D levels (at least 25 nmol/L) prior to supplementation, according to Adrian [… read more]
In an unusual turn, the Society for Critical Care Medicine (SCCM) is advising against implementation of the one-hour sepsis bundle originally advocated in Spring 2018 by committee members of its Surviving Sepsis Campaign. SCCM and American College of Emergency Physicians (ACEP) issued a joint statement in which they acknowledged “concerns expressed about the recently released Surviving [… read more]
Get PulmCCM’s Weekly Email Update
Stay up-to-date in pulmonary and critical care. No spam.